Showing results (111-120 of 155) with videos related to
Sort By:
Pageof 16
The Oncologist|May 4, 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaHani Babiker, Irene Brana, Daruka Mahadevan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsJosep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.Cancer|July 23, 2026
Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansionEugene Shenderov, Manish R Sharma, Elena Garralda, et al.Pageof 16